CXCR2 and head and neck squamous cell carcinoma: Inhibition of CXCR1 and CXCR2 signaling via SX-682, a small molecule inhibitor currently under evaluation in the clinic, allowed several human and murine HPV-negative HNSCC models to be sensitized to the cytotoxic activity of docetaxel in vitro and in vivo.